ArticlemSphere2020
A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring
Open access · goldAbstract read
In one paragraph
Article in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Characterization of Carbapenem-ResistantInfection and drug resistance · 2026Article
- Emerging resistance to novel β-lactam β-lactamase inhibitor combinations in Klebsiella pneumoniae bearing KPC variants.Journal of global antimicrobial resistance · 2025Article
- Global Epidemiology and Antimicrobial Resistance of Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Gram-Negative Clinical Isolates: A Review.Microorganisms · 2025Review
- Impact of the double deletion ΔG242-T243 in KPC-2 in the effectiveness of ceftazidime-avibactam and imipenem-relebactam.Antimicrobial agents and chemotherapy · 2025Article
- Phenotypic Ultra-Rapid Antimicrobial Susceptibility Testing for Ceftazidime-Avibactam: In Support of Antimicrobial Stewardship.Microorganisms · 2025Article
- Global epidemiology and resistance-related mutations of ceftazidime-avibactam-resistantFrontiers in cellular and infection microbiology · 2025Article
- Detection of hidden antibiotic resistance through real-time genomics.Nature communications · 2024Article
- KPC-2 allelic variants inMicrobiology spectrum · 2024Article
- Trematocine-derived antimicrobial peptides from the Antarctic fishFrontiers in microbiology · 2024Article
- Review
- Antimicrobial resistance in Gram-negative bacilli in Spain: an experts' view.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Article
- Mapping the determinants of catalysis and substrate specificity of the antibiotic resistance enzyme CTX-M β-lactamase.Communications biology · 2023Article
- Mobilization of theFrontiers in microbiology · 2023Article
- Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam.WIREs mechanisms of disease · 2022Review
- Article
- The Rapid Emergence of Ceftazidime-Avibactam Resistance Mediated by KPC Variants in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Diversity of Ceftazidime-Avibactam Resistance Mechanism in KPC2-ProducingInfection and drug resistance · 2022Article
- Emergence of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in a Widespread ST11 Carbapenem-ResistantFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Siqiang Niu *Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China siqiangniu@cqmu.edu.cn Liang.Chen@hmh-cdi.org.
Kalyan D Chavda *Hackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Jie WeiDepartment of Laboratory Medicine, West China Second University Hospital, and Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, China.
Chunhong ZouCollege of Laboratory Medicine, Chongqing Medical University, Yuzhong District, Chongqing, China.
Steven H MarshallResearch Service, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA.
Puneet DhawanMolecular Resource Facility and Department of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA.
Deqiang WangCollege of Laboratory Medicine, Chongqing Medical University, Yuzhong District, Chongqing, China.
Robert A BonomoResearch Service, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA.
Barry N KreiswirthHackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Liang ChenHackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA siqiangniu@cqmu.edu.cn Liang.Chen@hmh-cdi.org.ORCID 0000-0001-5845-2235
Hackensack Meridian Health · USChongqing Medical University · CNLouis Stokes Cleveland VA Medical Center · USRutgers, The State University of New Jersey · USSichuan University · CNThe Affiliated Yongchuan Hospital of Chongqing Medical University · CN
Funding
The molecular basis of the epidemic blaKPC gene KlebsiellaR01AI090155 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI KREISWIRTH, BARRY NEAL · 2011 to 2021
$7.2MUnderstanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MNIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI090155NIAID NIH HHS R01 AI100560
Abstract
Ceftazidime-avibactam is a potent antibiotic combination against
Indexed as
Anti-Bacterial AgentsAzabicyclo CompoundsBacterial Proteinsbeta-LactamasesCarbapenemsCeftazidimeDrug CombinationsDrug Resistance, Multiple, BacterialGenome, BacterialHumansKlebsiella InfectionsKlebsiella pneumoniaeMicrobial Sensitivity TestsNew York CityPlasmidsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsCeftazidimeDrug Combinationsantimicrobial resistancecarbapenemceftazidime-avibactamKPCplasmidselection
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.